Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
26.30%
↑ 123% above average
Average (22q)
-112.58%
Historical baseline
Range
High:88.12%
Low:-1505.56%
Volatility
-1415.7%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 26.30% |
| Q2 2025 | -1505.56% |
| Q1 2025 | 75.00% |
| Q4 2024 | -323.53% |
| Q3 2024 | 5.24% |
| Q2 2024 | 24.81% |
| Q1 2024 | -14.11% |
| Q4 2023 | -3.31% |
| Q3 2023 | 20.75% |
| Q2 2023 | 4.81% |
| Q1 2023 | -698.51% |
| Q4 2022 | 88.12% |
| Q3 2022 | -91.80% |
| Q2 2022 | 47.15% |
| Q1 2022 | 19.05% |
| Q4 2021 | -69.19% |
| Q3 2021 | 22.33% |
| Q2 2021 | -17.56% |
| Q1 2021 | -39.50% |
| Q4 2020 | -7.38% |
| Q3 2020 | 64.69% |
| Q2 2020 | -217.05% |
| Q1 2020 | 0.00% |